BioTuesdays

Tag - CMMB

Chemomab-Therapeutics

Cantor starts Chemomab Therapeutics at OW; PT $45

Cantor Fitzgerald initiated coverage of Chemomab Therapeutics (NASDAQ:CMMB) with an “overweight” rating and $45 price target. The stock closed at $16.07 on May 25. Chemomab is a clinical-stage biotech company focusing...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.